David Elsley
Fundador en CARDIOL THERAPEUTICS INC. .
Fortuna: 3 M $ al 31/05/2024
Perfil
David G.
Elsley is the founder.
He founded Vasogen, Inc. in 1990 and held the title of Director until 2009.
He also founded Cardiol Therapeutics, Inc. in 2017 and currently holds the titles of President, Chief Executive Officer & Director.
Mr. Elsley has an MBA from the University of Western Ontario and the Richard Ivey School of Business.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 29/02/2024 | 1 154 500 ( 1.67% ) | 3 M $ | 31/05/2024 |
Cargos activos de David Elsley
| Empresas | Cargo | Inicio |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Fundador | 19/01/2017 |
Antiguos cargos conocidos de David Elsley.
| Empresas | Cargo | Fin |
|---|---|---|
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Fundador | 23/10/2009 |
Formación de David Elsley.
| Richard Ivey School of Business | Masters Business Admin |
| University of Western Ontario | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| CARDIOL THERAPEUTICS INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
- Bolsa de valores
- Insiders
- David Elsley
